These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27810230)

  • 21. Transformative therapies for rare CFTR missense alleles.
    Oliver KE; Han ST; Sorscher EJ; Cutting GR
    Curr Opin Pharmacol; 2017 Jun; 34():76-82. PubMed ID: 29032041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272-26A > G/Q493X.
    Pallin M; Daley CP
    J Cyst Fibros; 2020 Jan; 19(1):e3-e4. PubMed ID: 31771899
    [No Abstract]   [Full Text] [Related]  

  • 23. Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement.
    Heltshe SL; Rowe SM; Skalland M; Baines A; Jain M;
    Am J Respir Crit Care Med; 2018 Jun; 197(11):1483-1486. PubMed ID: 29256624
    [No Abstract]   [Full Text] [Related]  

  • 24. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
    Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
    An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The march towards CFTR modulator access for all people with CF: The end of the beginning.
    VanDevanter DR
    J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
    [No Abstract]   [Full Text] [Related]  

  • 27. Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experience.
    Dagan A; Cohen-Cymberknoh M; Shteinberg M; Levine H; Vilozni D; Bezalel Y; Bar Aluma BE; Sarouk I; Ashkenazi M; Lavie M; Tsabari R; Blau H; Kerem E; Bentur L; Efrati O; Livnat G
    Respir Med; 2017 Oct; 131():225-228. PubMed ID: 28947035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
    Munce D; Lim M; Akong K
    Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A safety evaluation of ivacaftor for the treatment of cystic fibrosis.
    McColley SA
    Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
    Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
    Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
    Elborn JS; Davies J
    Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
    [No Abstract]   [Full Text] [Related]  

  • 32. Lumacaftor/ivacaftor combination therapy for cystic fibrosis: A nationwide survey among clinicians.
    Casciaro R; Costa S; Dang P; Majo F; Ros M
    Clin Respir J; 2018 Apr; 12(4):1767-1768. PubMed ID: 28759146
    [No Abstract]   [Full Text] [Related]  

  • 33. Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use.
    Megalaa R; Gopalareddy V; Champion E; Goralski JL
    Pediatr Pulmonol; 2019 Aug; 54(8):E16-E18. PubMed ID: 31066218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.
    Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G
    PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CORK Study in Cystic Fibrosis: Sustained Improvements in Ultra-Low-Dose Chest CT Scores After CFTR Modulation With Ivacaftor.
    Ronan NJ; Einarsson GG; Twomey M; Mooney D; Mullane D; NiChroinin M; O'Callaghan G; Shanahan F; Murphy DM; O'Connor OJ; Shortt CA; Tunney MM; Eustace JA; Maher MM; Elborn JS; Plant BJ
    Chest; 2018 Feb; 153(2):395-403. PubMed ID: 29037527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
    Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
    Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR.
    Birket SE; Davis JM; Fernandez-Petty CM; Henderson AG; Oden AM; Tang L; Wen H; Hong J; Fu L; Chambers A; Fields A; Zhao G; Tearney GJ; Sorscher EJ; Rowe SM
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1271-1282. PubMed ID: 32584141
    [No Abstract]   [Full Text] [Related]  

  • 38. Ivacaftor restores CFTR-dependent sweat gland fluid secretion in cystic fibrosis subjects with S945L alleles.
    Kim J; Davies Z; Dunn C; Wine JJ; Milla C
    J Cyst Fibros; 2018 Mar; 17(2):179-185. PubMed ID: 29279204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis.
    Gramegna A; Contarini M; Aliberti S; Casciaro R; Blasi F; Castellani C
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
    Ramsey BW; Welsh MJ
    Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.